JPRN-jRCTs051200038
Completed
Phase 1
Development of a new cancer diagnostic method based on metabolites derived from samples before and after oral administration of 13C-labeled glucose in patients with PET-positive lung cancer : Single-arm, exploratory clinical trial
Yoshida Masaru0 sites6 target enrollmentJuly 30, 2020
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Resectable primary lung cancer
- Sponsor
- Yoshida Masaru
- Enrollment
- 6
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •(1\) Patients who are at least 20 years old and under 80 years old at the time of obtaining consent
- •(2\) PET\-positive primary lung cancer patients who can be surgically resected
- •(3\) Patients who have given their informed consent to participate in this clinical study
Exclusion Criteria
- •(1\) Patients with other cancers
- •(2\) Other patients judged inappropriate by the person in charge of this clinical study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Development of cancer immune evaluation toolNeoplasmsKCT0002469Seoul Songdo Hospital500
Recruiting
Not Applicable
Development of early cancer diagnosis technique using blood sample by Raman spectroscopyJPRN-UMIN000034306Showa University Koto Toyosu Hospital2,000
Completed
Not Applicable
sing stool samples in the diagnosis of mitochondrial diseaseISRCTN15670031ewcastle upon Tyne Hospitals NHS Foundation Trust47
Not yet recruiting
Not Applicable
A novel method to improve the detection of cancer and metastases by peptide scanning under the protection of enzyme inhibitors: PepProtect 1NL-OMON44441Erasmus MC, Universitair Medisch Centrum Rotterdam12
Completed
Not Applicable
A novel technique for cellular diagnosis utilizing scanning electron microscope.thoracic malignancyJPRN-UMIN000025724ational Cancer Center Hospital100